{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T15:29:30Z","timestamp":1781796570027,"version":"3.54.5"},"reference-count":20,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T00:00:00Z","timestamp":1741046400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.clml.2025.03.001","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T08:12:43Z","timestamp":1741162363000},"page":"e533-e540.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-World Data on Outcome of Burkitt Lymphoma and Burkitt Leukemia Treated According to the GMALL B-ALL\/NHL 2002 Protocol: A Tertiary Center Experience"],"prefix":"10.1016","volume":"25","author":[{"given":"Ricardo","family":"Kosch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6494-5105","authenticated-orcid":false,"given":"Christoph","family":"Schaefers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Frenzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Fiedler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Weisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Bokemeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Seidel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Finn-Ole","family":"Paulsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clml.2025.03.001_bib0001","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/ijc.2910170108","article-title":"Characteristic chromosomal abnormalities in biopsies and lymphoid-cell lines from patients with burkitt and non-burkitt lymphomas","volume":"17","author":"Zech","year":"1976","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.clml.2025.03.001_bib0002","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1182\/blood.V87.2.495.bloodjournal872495","article-title":"Improved outcome in adult B-cell acute lymphoblastic leukemia","volume":"87","author":"Hoelzer","year":"1996","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clml.2025.03.001_bib0003","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1093\/annonc\/mdi403","article-title":"Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol","volume":"16","author":"Divin\u00e9","year":"2005","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.clml.2025.03.001_bib0004","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1200\/JCO.1999.17.8.2461","article-title":"Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia","volume":"17","author":"Thomas","year":"1999","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clml.2025.03.001_bib0005","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1080\/10428190601078944","article-title":"CODOX-M\/IVAC (NCI 89-C-41) in children and adolescents with Burkitt's leukemia\/lymphoma and large B-cell lymphomas: A 15-year monocentric experience","volume":"48","author":"Moleti","year":"2007","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.clml.2025.03.001_bib0006","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1182\/blood-2008-03-145128","article-title":"A prospective clinicopathologic study of dose-modified CODOX-M\/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC\/NCRI LY10 trial)","volume":"112","author":"Mead","year":"2008","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2025.03.001_bib0007","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1093\/annonc\/mdf253","article-title":"An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study","volume":"13","author":"Mead","year":"2002","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.clml.2025.03.001_bib0008","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/cncr.21776","article-title":"Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia","volume":"106","author":"Thomas","year":"2006","journal-title":"Cancer"},{"issue":"22","key":"10.1016\/j.clml.2025.03.001_bib0009","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1200\/JCO.20.00303","article-title":"Multicenter study of risk-adapted therapy with dose-adjusted EPOCH-R in adults with untreated burkitt lymphoma","volume":"38","author":"Roschewski","year":"2020","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.clml.2025.03.001_bib0010","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1182\/blood-2014-03-563627","article-title":"Improved outcome of adult Burkitt lymphoma\/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial","volume":"124","author":"Hoelzer","year":"2014","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clml.2025.03.001_bib0011","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1182\/blood.V110.11.518.518","article-title":"High survival rate in adult Burkitt's lymphoma\/leukemia and diffuse large B-cell lymphoma with mediastinal involvement","volume":"110","author":"Hoelzer","year":"2007","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2025.03.001_bib0012","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1093\/annonc\/mdt058","article-title":"Impact of chemotherapy regimen and rituximab in adult Burkitt lymphoma: a retrospective population-based study from the Nordic Lymphoma Group","volume":"24","author":"W\u00e4sterlid","year":"2013","journal-title":"Ann Oncol"},{"issue":"20","key":"10.1016\/j.clml.2025.03.001_bib0013","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1002\/cncr.28264","article-title":"Population-based prognostic factors for survival in patients with Burkitt lymphoma: an analysis from the Surveillance, Epidemiology, and End Results database","volume":"119","author":"Castillo","year":"2013","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.clml.2025.03.001_bib0014","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.clml.2025.03.001_bib0015","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1200\/JCO.20.03288","article-title":"Burkitt Lymphoma International Prognostic Index","volume":"39","author":"Olszewski","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clml.2025.03.001_bib0016","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1002\/onco.13603","article-title":"Standardized supportive care documentation improves safety of high-dose methotrexate treatment","volume":"26","author":"Alsdorf","year":"2021","journal-title":"The Oncologist"},{"issue":"5","key":"10.1016\/j.clml.2025.03.001_bib0018","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.clml.2025.03.001_bib0019","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa1308392","article-title":"Low-intensity therapy in adults with Burkitt's lymphoma","volume":"369","author":"Dunleavy","year":"2013","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.clml.2025.03.001_bib0020","doi-asserted-by":"crossref","first-page":"e966","DOI":"10.1016\/S2352-3026(23)00279-X","article-title":"R-CODOX-M\/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma (HOVON\/SAKK): final results of a multicentre, phase 3, open-label, randomised trial","volume":"10","author":"Chamuleau","year":"2023","journal-title":"Lancet Haematol"},{"issue":"Supplement_1","key":"10.1016\/j.clml.2025.03.001_bib0021","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1182\/blood-2019-122990","article-title":"Outcomes of patients with newly-diagnosed burkitt lymphoma (BL) and Central nervous system (CNS) involvement treated in the modern era: a multi-institutional real-world analysis","volume":"134","author":"Zayac","year":"2019","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025000783?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025000783?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T13:52:05Z","timestamp":1749477125000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025000783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":20,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S2152265025000783"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.03.001","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Data on Outcome of Burkitt Lymphoma and Burkitt Leukemia Treated According to the GMALL B-ALL\/NHL 2002 Protocol: A Tertiary Center Experience","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}